Status: Not yet recruiting
Study of CU06-1004 in Patients With Daibetic Macular Edema
This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 24 weeks. The study will have a 1:1:1 randomization (CU06-1004 200mg: CU06-1004 300mg: Placebo).
Participants needed: 156
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Curacle Co., Ltd.Updated: Mar 10, 2026
Eligibility criteria
Have read, understood, and signed the informed consent form. [+9]
Has only 1 functional eye, even if the eye met all other study requirements, or... [+36]